David Loeb
Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Ewing sarcoma is an aggressive bone and soft-tissue cancer affecting adolescents and young adults. In vitro and in vivo models of Ewing sarcoma have been instrumental in advancing our understanding of Ewing sarcoma biology and essential in evaluating potential therapies, particularly for metastatic or relapsed disease for which effective treatment options remain limited. Through an international collaborative effort between the Children’s Oncology Group Bone Tumor Committee and the Euro Ewing Consortium, we review the current landscape of preclinical modeling used in Ewing sarcoma research encompassing both in vitro (cell lines and tumor organoids) and in vivo (mouse and nonmammalian xenografts) model systems. We discuss factors that can influence experimental results, provide testing considerations for both in vitro and in vivo studies, and descriptions of existing preclinical data repositories. We highlight current needs in Ewing sarcoma modeling and the importance of enhanced international cooperative research and patient advocacy efforts which will be critical in expanding our resources of biologically relevant Ewing sarcoma models to enable translation of preclinical findings into effective therapeutic strategies for patients with Ewing sarcoma.
Year:
2026
Supplementary Figure S4: DFMO inhibits sarcosphere formation. Quantification of the data presented in Figure 2. The indicated cells were grown in non-adherent conditions with non-differentiating media and treated with the indicated concentration of DFMO, in 5 mM DFMO supplemented with spermidine (5 µM) and aminoguanidine (1 mM), with spermidine and aminoguanidine alone, or with 10 mM DFMO for 5 days beginning after 5 days to allow spheroids to form. Indicated conditions were statistically significantly different from each other by Student’s t test.
Year:
2025
Supplementary Figure S3: DFMO causes a cell cycle arrest. Histograms demonstrate the percentage of TC71 cells (A) and SK-ES-1 cells (C) in the G1 (purple), S (yellow), and G2/M (green) phases of the cell cycle in control cultures and in cultures treated with DFMO at the IC50 estimated from the proliferation assays (TC71: 650 µM, SK-ES1: 1 mM, MHH-ES1: 2 mM) for 72 hours. Representative results of experiments performed 2 separate times are shown. Quantification of the histograms in panel A are shown in panel B, and quantification of the histograms in panel C are shown in panel D. Statistical significance of the difference in overall distribution of cells within the cell cycle was tested using the χ 2 test.
Year:
2025
Supplementary Figure S9: DFMO-mediated inhibition of sarcosphere formation is rescued by inhibitors of ferroptosis but not by inhibition of apoptosis. MHH-ES1 cells (A) and SK-ES1 cells (B) were grown in non-adherent conditions with non-differentiating media and treated with either DFMO (1 or 5 mM, as indicated) or 1 mM DFMO supplemented with Spermine/Aminoguanidine, Ferrostatin-1, Liproxstatin-1, N-acetylcysteine (NAC), or Q-VD-OPh. + indicates 1 mM DFMO. P indicates cells treated with 10 mM DFMO after spheroid formation. Spheroid formation was quantified in triplicate samples, and experiment was repeated 3 times. 1 mM DFMO caused a statistically significant decrease in spheroid formation (MHH-ES1 p = 0.0039, SK-ES1 p = 0.0023). Ferrostatin (MHH-ES1 p = 0.0006, SK-ES1 p = 0.0023), liproxstatin (MHH-ES1 p = 0.0065, SK-ES1 p = 0.0005)), and NAC (MHH-ES1 p = 0.007, SK-ES1 p = 0.0002) each caused a statistically significant increase in spheroid formation in the presence of 1 mM DFMO compared with 1 mM DFMO alone. In contrast, Q-VD did not rescue spheroid formation in the presence of 1 mM DFMO. None of the cell death inhibitors (spermidine, ferrostatin, liproxstatin, NAC, or Q-VD-OPh) resulted in a statistically different number of spheroids compared to untreated cells.
Year:
2025
Supplementary Figure S10: Dissemination of Ewing sarcoma tumor cells alters the expression of multiple ferroptosis-related genes. Normalized read counts of key genes from the RNA-seq experiment described in Figure 5. In brief, tumors composed of TdTomato-labeled TC-71 cells were implanted in the tibias of NSG mice. When tumors reached 1.5 cm in diameter, Ewing sarcoma cells were recovered from lungs, bone marrow, and the primary tumor by flow cytometry. RNA was isolated from these cells and analyzed by RNA sequencing.
Year:
2025
Supplementary Figure S1: DFMO inhibits Ewing sarcoma proliferation in vitro. TC71 cells (A) and SK-ES-1 cells (D) were treated with DFMO at various concentrations. Error bars represent 95% confidence interval for triplicate evaluation of each sample. This data is representative of 3 independent experiments demonstrating a dose-dependent inhibition of proliferation with exposure to DFMO. TC71 cells (B) and SK-ES-1 cells (E) were treated with the indicated concentrations of DFMO. After 4 days, DFMO was removed and replaced with fresh media without DFMO. Resumption of proliferation was observed in all 3-cell lines. TC71 cells (C) and SK-ES-1 cells (F) were treated with the indicated concentrations of DFMO. After 4 days, fresh DFMO was added with or without the addition of spermidine (5 µM) and aminoguanidine (1 mM). Proliferation was measured over an additional 6 days utilizing the Incucyte Live-Cell Analysis System, and cells were noted to proliferate in cultures supplemented with spermidine and aminoguanidine.
Year:
2025
Purpose: Despite decades of clinical trials, no progress has been made in improving the survival of patients with Ewing sarcoma who either present with metastatic disease or suffer a metastatic relapse. In our preclinical models, we found differential levels of polyamines in tumors that metastasize compared with tumors that do not, leading us to investigate the potential for D,L-α-difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, to prevent Ewing sarcoma metastasis. Experimental Design: The effect of DFMO on Ewing sarcoma cell lines in vitro was studied by measuring proliferation, sphere formation, and clonogenic growth in soft agar. The effect in vivo was investigated using our orthotopic implantation/amputation model of metastasis. Transcriptomic changes were evaluated by RNA sequencing. Results: DFMO causes a cell cycle arrest and inhibits both sarcosphere formation and clonogenic growth in soft agar. In vivo , DFMO slows primary tumor growth and inhibits metastasis. RNA sequencing demonstrated gene expression patterns consistent with induction of ferroptosis caused by polyamine depletion, which was validated in vitro by demonstrating that DFMO treatment induces lipid peroxidation, and ferrostatin-1 and liproxstatin-1 allow sphere formation even in the presence of DFMO. Conclusions: DFMO slows the growth of Ewing sarcoma cells in vitro , with a profound impact on sphere formation and clonogenic growth, and affects all aspects of Ewing sarcoma tumorigenesis, including tumor initiation, tumor growth, and metastasis, probably through induction of ferroptosis mediated by polyamine depletion. Our results provide preclinical justification to test the ability of DFMO to prevent metastatic recurrence in patients with Ewing sarcoma.
Year:
2025
Supplementary Figure S8: DFMO induces lipid peroxidation. Twenty thousand MHH-ES1 cells (A and B) or SK-ES1 cells (C and D) were plated in ultra-low attachment plates and treated with (B and D) or without (A and C) 5 mM DFMO. After 24 hours, cells were collected, incubated with 5 µM BODIPY581/591 for 30 minutes, and green and red fluorescence was evaluated by flow cytometry. The amount of green fluorescence reflects the amount of peroxidated lipid. In control conditions, only 3.54% of the MHH-ES1 cells and 22.8% of the SK-ES1 cells exhibited green fluorescence, whereas 25.1% of DFMO-treated MHH-ES1 cells and 41.4% of DFMO-treated SK-ES1 cells exhibited green fluorescence.
Year:
2025
Supplementary Figure S6: 2% DFMO diminishes polyamine production in vivo. Fragments of the JHHESX3 PDX were implanted in NSG mice either subcutaneously or in the tibia (orthotopic) and mice were randomly assigned to receive either regular drinking water or water supplemented with 2% DFMO (w/v). (A) Concentrations of both putrescine (p = 0.0001) and spermidine (p = 0.024) measured in the urine from mice with orthotopic tumors were significantly lower in DFMO-treated mice compared to control. (B) Ornitine Decarboxylase (ODC) activity was lower in orthotopic tumors compared with subcutaneous tumors (p = 0.014), and ODC activity was also lower in DFMO-treated mice with orthotopic tumors compared with control (p = 0.018). Polyamine levels were measured in tumor samples excised from tumors implanted subcutaneously (C) or orthotopically (D). Regardless of site of implantation, levels of both putrescine and spermidine were lower in tumors collected from DFMO-treated mice compared with control. DFMO treatment did not affect the concentration of spermine, as has been previously reported (40).
Year:
2025
Supplementary Figure S7: DFMO does not induce caspase activity. 300,000 MHH-ES1 cells (A) or SK-ES1 cells (B) were plated in RPMI + 10% FBS. After 24 hours, the media was removed, and fresh media supplemented with Incucyte Caspase-3/7 Dye for Apoptosis was added. DFMO was added at the indicated concentrations of 0.5 µM to 10 mM. Etoposide (3 µM) was used as a positive control. Plates were inserted into the Incucyte Live-Cell Analysis System and caspase activity was measured utilizing live-cell time-lapse imaging at 24 hours. Error bars represent 95% confidence interval for triplicate evaluation of each sample. This data is representative of 3 independent experiments. Whereas etoposide treatment results in profound activation of caspase 3 in all 3 cell lines tested, this was not detected in cells treated with DFMO, even at the highest doses tested. ** = p
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Collaborators (26)
Eric Sandler
Department Chair
Nemours Children's Health System
Christine A Pratilas
Vice Chair for Pediatric Oncology
Johns Hopkins University School of Medicine
Zhanjun Hou
Professor (Research)
Wayne State University
Patrick Grohar
Professor of Pediatrics
University of Michigan
Alice Soragni
University of California
Tracy Murray Stewart
Assistant Professor
Johns Hopkins University
Javier Oesterheld
Clinical (Full) Professor
Wake Forest University
Shrey Patel
Albert Einstein College of Medicine
Eleni Marina Tomazou
-
Kelly M. Bailey
Associate Professor, Director AYA Translational Oncology
Mayo Clinic
Robert Casero
Professor and Associate Director
Johns Hopkins University School of Medicine
Masanori Hayashi
Assistant Professor
University of Colorado Boulder
Adam Shlien
Wellcome Sanger Institute
Yuqi Tan
Stanford University
Leo Mascarenhas
Division Chief and Director, Pediatric Hematology-Oncology, Guerin Children's; Director, Sarcoma Program, Cedars-Sinai Cancer
Cedars-Sinai Medical Center
Joyce Ohm
Chair, John and Santa Palisano Endowed Chair
Roswell Park Comprehensive Cancer Center
James Amatruda
Chief
University of Southern California Keck School of Medicine
Shireen Ganapathi
Assistant Professor of Pediatrics
University of Washington
Jun Yin
Associate Professor
H Lee Moffitt Cancer Center and Research Institute
Brooke Fridley
Director
Children's Mercy Hospital
Patrick Cahan
johns hopkins university school of medicine 1 department of biomedical engineering
Hongwen Deng
Founding Director
Tulane University School of Medicine
Emi Caywood
Director, Transplant and Cellular Therapy
Alfred I DuPont Hospital for Children
Matteo Trucco
Associate Professor
Cleveland Clinic
Scott Borinstein
Professor
Vanderbilt University Medical Center
Lars Wagner
division of pediatric hematology‐oncology duke university medical center durham north carolina usa
Make your next move.
Prepare your application
Review drafts before you send them.